Efficacy News and Research

RSS
NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome

NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles

Human Genome Sciences second-quarter revenues increase to $38.8 million

Human Genome Sciences second-quarter revenues increase to $38.8 million

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Baxter second-quarter global sales increase 2% to $3.2 billion

Baxter second-quarter global sales increase 2% to $3.2 billion

Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis

Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis

Repros granted IRB approval to commence low dose Proellex study

Repros granted IRB approval to commence low dose Proellex study

Euthymics Bioscience completes $24 million Series A financing

Euthymics Bioscience completes $24 million Series A financing

Predator-released chemicals function as warning signals for egg-laying mosquitoes

Predator-released chemicals function as warning signals for egg-laying mosquitoes

Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals

Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals

Elan total revenue increases 10% to $579.4 million for first half of 2010

Elan total revenue increases 10% to $579.4 million for first half of 2010

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Flat global funding for HIV prevention research could have serious consequences: Report

Flat global funding for HIV prevention research could have serious consequences: Report

ASP EVOTECH Endoscope Cleaner and Reprocessor technology superior to manual cleaning: Study

ASP EVOTECH Endoscope Cleaner and Reprocessor technology superior to manual cleaning: Study

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.